At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top California based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Christine A. Tsingos
EVP & CFO of Bio-Rad Laboratories
Ms. Christine A. Tsingos is Chief Financial Officer, Executive Vice President of Bio Rad Laboratories Inc. Previously, she was the Chief Operating Officer and Chief Financial Officer at Attest Systems, Inc., a provider of information technology asset discovery and management tools, from August 2002 to November 2002. Prior to that, Ms. Tsingos was a consultant to Attest Systems, Inc. from October 2000 to July 2002. She was the Chief Financial Officer at Tavolo, Inc., an online retailer of gourmet cookware and food, from November 1999 to September 2000, and she was Treasurer, and later Vice President and Treasurer, of Autodesk, Inc., a developer of design software, from May 1990 to November 1999.
Follow Christine A. Tsingos:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Gene Castagnini
COO, CFO, CAO & Co-founder of Biocare Medical
Gene J. Castagnini, MS, MBA, co-founded Biocare Medical LLC in 1997 and serves as its Co-Owner and Chief Financial Officer. Gene Castagnini serves as the Chief Operating Officer and Executive Vice President of Biocare Medical, LLC Gene Castagnini served as the Chief Administrative Officer and Chief Financial Officer of BioGenex Laboratories. Inc., for 10 years. Gene Castagnini’s experience includes 15 years as a Director and Officer of Medi-Physics Inc., formerly a Hoffmann-La Roche Inc. subsidiary. Gene Castagnini has a BS in accounting and an MBA in Human Resource Management from the California State University school systems.
Follow Gene Castagnini:
About Biocare Medical: Biocare Medical is a provider of immunohistochemistry instrumentation.
Gerard van Hamel Platerink
Chief Financial Officer of Genalyte
Board Member at HealthMine, MedAvail Technologies & Genalyte.
Follow Gerard van Hamel Platerink:
About Accuitive Medical Ventures, Genalyte, Redmile Group: Genalyte is a life sciences company developing and commercializing innovative next-generation multiplexing technology.
Shaun Holt
CFO of Berkeley Lights
Shaun joined Berkeley Lights in November 2015 and was appointed Chief Financial Officer in March 2016. Prior to becoming CFO, Shaun was Vice President of Finance. Prior to joining Berkeley Lights, Shaun spent 7 ½ years at Illumina, Inc. heading up various aspects of their Finance organization. His roles included Sr. Director, Global Head of R&D and Business Unit Finance, EMEA Head of Finance, Accounting and Facilities, and Commercial FP&A. He earned a B.S. in Finance from California State University, Stanislaus.
Follow Shaun Holt:
About Berkeley Lights: Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Tim Cabral
Advisor (Former CFO) of Veeva
As CFO, Tim is responsible for all aspects of financial management and G&A operations. He brings over 20 years of technology finance background and nearly 10 years of software finance and operations background. Prior to joining Veeva Systems, Tim served as CFO/COO for Walsh Wireless, a wireless solutions and services company and as CFO/CoFounder of Agistics, a start-up focused on employee management services. Tim also spent more than 7 years at PeopleSoft, Inc., where he held various positions, including VP of Products & Technology Finance and Senior Director of Corporate FP&A. During his tenure as VP of Finance, Tim created and built the Operational Controller team and developed an influential business partnership model with General Managers who owned business units driving upwards of $250m in revenue. Prior to PeopleSoft, Tim served in finance positions at Chiron Corporation and LSI Logic. Tim holds a MBA in Finance and a Bachelors degree in Finance from Santa Clara University.
Follow Tim Cabral:
About Veeva: Veeva Systems is a provider of cloud-based business solutions for the global life sciences industry.
Georgia Erbez
Chief Financial Officer of Harpoon Therapeutics
Georgia Erbez currently works as the Chief Financial Officer for Harpoon Therapeutics. She previously worked at Artelo Biosciences, Inc. as the Member Board Of Directors.
Follow Georgia Erbez:
About Harpoon Therapeutics: Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Howard Horn
CFO of Vir Biotechnology
Howard Horn is the Chief Financial Officer of VIR. Previously, he led the Financial Planning and Corporate Finance functions at Biogen. Prior to joining Biogen, he held positions of increasing responsibility and was focused on the life sciences as a consultant with McKinsey & Company and as an equity research analyst at UBS. Howard holds an M.B.A from the Wharton School of the University of Pennsylvania and a B.A in Economics from Princeton University.
Follow Howard Horn:
About Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Enakshi Singh
Chief Financial Officer of Zymergen
Prior to joining Zymergen, Ena was focused on semiconductor investments at Mubadala, Abu Dhabi’s sovereign wealth fund. She spent the previous seven years in investment banking, initially at Salomon Smith Barney’s Latin America Group, later working for Merrill Lynch’s Technology Investment Banking Group. Ena studied at Cornell University and received her graduate degree at MIT Sloan School of Management.
Follow Enakshi Singh:
About Zymergen: Zymergen is a biotechnology company that specializes in machine learning, big data, and artificial intelligence.
Gary Martell
CFO of Skyhawk Therapeutics
Follow Gary Martell:
About Blu Homes, Skyhawk Therapeutics: Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
Kathryn E. Falberg
Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals
Kathryn Falberg was appointed our Executive Vice President and Chief Financial Officer in March 2012. She served as our Senior Vice President and Chief Financial Officer from 2009 to 2012. Her responsibilities include finance, strategy, corporate development and IT. From 1995 through 2001, Kathryn Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. From 2001 through 2008, Kathryn Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm, where she worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies. From February to November 2009, she was Chief Financial Officer and Chief Operating Officer at ARCA biopharma, Inc., a biopharmaceutical company. Kathryn Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant (inactive). Kathryn Falberg currently serves on the boards, and is chair of the audit committees, of biopharmaceutical companies Halozyme Therapeutics, Inc. and Medivation, Inc.
Follow Kathryn E. Falberg:
About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
Ken Myszkowski
Chief Financial Officer of Arrowhead Pharmaceuticals
Follow Ken Myszkowski:
About Arrowhead Pharmaceuticals: Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Glenn S. Boehnlein
Chief Financial Officer & Vice President of Stryker
Follow Glenn S. Boehnlein:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Kim Witmer
Senior Vice President & Chief Financial Officer & Treasurer of Salk Institute for Biological Studies
Kim Witmer is Senior Vice President, Chief Financial Officer and Treasurer of the Salk Institute. She oversees all financial activities of the Salk, including financial reporting and treasury functions, research accounting, annual budgets, procurement, grants administration and endowment/investment management. Prior to joining the Salk, Witmer worked for the international accounting firm of Deloitte & Touche. Witmer also acts as past President of AIRI, the Association of Independent Research Institutes, as well as serving on AIRI’s Board of Directors and Government Affairs Committee. AIRI brings together nearly 100 independent, not-for-profit biomedical and behavioral research institutes whose mission is to enhance the ability of its members to improve human health and advance knowledge. Additionally, Witmer served as the Chief Financial Officer and Treasurer of the Sanford Consortium for Regenerative Medicine (SCRM), and currently holds a position on SCRM’s Administrative Council as the Salk representative. She is a Certified Public Accountant and holds a B.S. in business administration from San Diego State University.
Follow Kim Witmer:
About Salk Institute for Biological Studies: Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology.
Susan M. Kanaya
Senior Vice President, Finance, Chief Financial Officer and Secretary of ChemoCentryx
Ms. Susan M. Kanaya has served as our Senior Vice President, Finance, and Chief Financial Officer since January 2006, and Secretary since February 2006. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.
Follow Susan M. Kanaya:
About ChemoCentryx: ChemoCentryx develops orally administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Henry Edmunds
acting CFO of Sepragen
Dr. Edmunds is currently acting as Chief Financial Officer of Sepragen. He also serves as President of Biopheresis. Previously, he served as Vice President and Chief Financial Officer of Prometheus, a pharmaceutical company. He also served as Vice President of Corporate Development and Chief Financial Officer of SangStat Medical Corporation, and as Director of Business development at Genencor, Inc. Dr. Edmunds received his Ph.D. in Biotechnology from the University of California, Berkeley and his M.B.A. from the Stanford School of Business.
Follow Henry Edmunds:
About Sepragen: Sepragen provides break-through products and processes to the biotechnology and nutraceutical industries.
Shalini Sharp
CFO of Ultragenyx Pharmaceutical
Shalini Sharp joined Ultragenyx in May 2012 as Chief Financial Officer and Senior Vice President, Finance. She is a member of the Senior Management Team and is responsible for leading the corporate finance function, including strategic financial planning, accounting, budgeting and forecasting, financial analysis, general risk analysis, and financing activities. Shalini Sharp is a member of the Board of Directors of Agenus Inc. (formerly Antigenics Inc.), a publicly traded biotechnology firm, where she served as Chief Financial Officer from 2006 to 2012. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development. Prior to Agenus, Shalini Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that company’s restructing. With 16 years of industry experience, Shalini Sharp has spearheaded numerous financing and business development transactions that have been critical to the success of Agenus and Elan. Prior to Elan, Shalini Sharp was a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices.
Follow Shalini Sharp:
About Ultragenyx Pharmaceutical: Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Bryan Giraudo
Chief Financial Officer & COO of Gossamer Bio
Mr. Giraudo is the Chief Financial Officer of Gossamer Bio. Previously, he was Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Bryan was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Bryan received his B.A. from Georgetown University.
Follow Bryan Giraudo:
About Gossamer Bio: Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
Aaron Freidin
Chief Financial Officer of Grail
Aaron Freidin is Chief Financial Officer at Grail.
Follow Aaron Freidin:
About Grail: Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
Martyn Ansell
Chief Financial Officer and Vice President, Finance of Molecular Devices
Martyn joined Molecular Devices in June 2012 as Vice President, Finance. Prior to joining Molecular Devices he was Chief Financial Officer of Vistec Semiconductor Systems, a global leader in the development and manufacture of electron-beam lithography equipment for the semiconductor industry. Prior to joining Vistec, Martyn spent over 12 years at Applied Materials, a manufacturer of semiconductor equipment, where he held a number of senior financial management positions in business development and within several product divisions. In addition, he has held positions at Coopers & Lybrand, in San Jose, California and Ernst & Young in the U.K. Martyn received a BA in Accounting and Finance with Honors from the Manchester Metropolitan University, Manchester, England and is a member of the American Institute of Certified Public Accountants.
Follow Martyn Ansell:
About Molecular Devices: Bioanalytical Systems and Solutions
David Lewis
Co-Founder & CFO of LunaDNA
David Lewis is a Co-Founder and Chief Financial Officer at LunaDNA and LunaPBC.
Follow David Lewis:
About Ganley Investment Group, LunaDNA, LunaPBC: The first and largest health and DNA research platform owned by its community.
Judy Koh
Managing Director/Chief Financial Officer of Bay City Capital
Judy Koh, MBA, CPA, is an Operating Partner and the Chief Financial Officer at Bay City Capital and has been with the firm since April 1998.
Follow Judy Koh:
About Bay City Capital, Illumina Ventures: Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Arthur Polk
Chief Financial Officer & Co-Founder of PetDx
Arthur Polk is the Chief Financial Officer and a Co-Founder at PetDx.
Follow Arthur Polk:
About PetDx: PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
Lauren Silvernail
CFO and EVP Corporate Development of Evolus
Lauren Silvernail is the Chief Financial Officer and Executive Vice President, Corporate Development at Evolus.
Follow Lauren Silvernail:
About Evolus: Evolus medical aesthetics focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments.
Paul Kim
Chief Financial Officer of Fulgent Therapeutics
Paul Kim has served as Fulgent Chief Financial Officer since 2016. Prior to his service for us, Mr. Kim served as Chief Financial Officer of Cogent, a publicly traded biometric identification services and product company from 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, or JNI, a publicly traded storage area network technology company, from 2002 until 2003, as Vice President, Finance and Corporate Controller at JNI from 1999 to 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from 1998 until 1999. From 1996 to 1998, Mr. Kim was the Corporate Controller for Interlink Computer Sciences, Inc., a publicly traded enterprise software company. From 1990 to 1996, Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.
Follow Paul Kim:
About Fulgent Therapeutics: Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics.
Paul Manners
Chief Financial Officer of Trak
Follow Paul Manners:
About Trak: Sandstone Diagnostics provides an integrated wellness technology that empowers consumers to measure, monitor, and improve their health.
Nathan Weems
Chief Financial Officer of VitalConnect
Nathan has accrued over 13 years of operational excellence in management roles spanning finance, business development, and marketing, most recently serving as Sr. Director of Finance at Natera, a public Bay Area biotech company. Earlier experience includes tenure at a top Wall Street investment bank and Big-4 accounting firm. Nathan brings expertise in accounting, due diligence, market research, fund raising and investor relations. He holds a BA from the University of Southern California and an MBA from Wharton. When his HP 12C is not within reach, you can usually find Nathan on two wheels or two skis exploring the outdoors with his family.
Follow Nathan Weems:
About VitalConnect: VitalConnect is a wearable biosensor technology for wireless hospital and remote patient monitoring.
Jonathan Tu
CFO & Co-Founder of Fluxergy
Jonathan Tu is the Chief Financial Officer and Co-Founder at Fluxergy.
Follow Jonathan Tu:
About Fluxergy: Fluxergy is a biotechnology company that offers point-of-care testing, PCR, and medical diagnostics.
Vikram Jog
CFO of Fluidigm
Vikram Jog has served as our Chief Financial Officer since February 2008. From April 2005 to February 2008, Mr. Jog served as Chief Financial Officer for XDx, Inc., a molecular diagnostics company. From March 2003 to April 2005, Mr. Jog was a Vice President of Applera Corporation and Vice President of Finance for its related businesses, Celera Genomics and Celera Diagnostics. From April 2001 to March 2003, Mr. Jog was Vice President of Finance for Celera Diagnostics and Corporate Controller of Applera Corporation. Mr. Jog holds a Bachelor of Commerce degree from Delhi University and an M.B.A. from Temple University. Mr. Jog is a member of the American Institute of Certified Public Accountants.
Follow Vikram Jog:
About Fluidigm: Fluidigm is a biotech tools company that creates microfluidic-based chips and instrumentation for biological research.
Mario Wanderley
Chief Financial Officer of Entrinsic Bioscience
Mario Wanderley is Managing Partner at VGP – Venture Growth Partners.
Follow Mario Wanderley:
About CitizenGlobal, Entrinsic Bioscience, Venture Growth Partners: Entrinsic Bioscience leverages gold standard science and game-changing amino acid technology.
Kaitlyn Arsenault
Chief Financial Officer of Skye Bioscience
Ms. Arsenault brings over 14 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology sectors.
Follow Kaitlyn Arsenault:
About Skye Bioscience: Skye Bioscience is a biopharmaceutical company focused on the discovery, development, and the commercialization.
David Pool
Chief Financial Officer of Ocunexus Therapeutics
Mr. Pool joined CoDa Therapeutics as Chief Financial Officer in July 2008. He has over 20 years investment banking and venture capital experience including privatization transactions, leasing, securitizations, venture capital raising and initial public offerings. Mr. Pool has raised over $50M for early stage Biotech companies. Mr. Pool’s responsibilities include all financial and accounting functions as well as driving CoDa’s fund raising process and business development activities. Prior to CoDa, Mr. Pool was Protemix Corporation’s Chief Operating and Financial Officer for 5 years. Mr. Pool holds a Bachelor of Commerce in accounting and business administration from the University of Canterbury and is a member of the Institute of Chartered Accountants of New Zealand.
Follow David Pool:
About Inflammx Therapeutics, Ocunexus Therapeutics: Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology.
Tom O’Neil
Chief Financial Officer of Protagonist Therapeutics
Tom O’Neil is the chief financial officer of [Arcadia Biosciences](https://www.crunchbase.com/organization/arcadia-biosciences#/entity), an agricultural technology company focused on developing products that benefit the environment and human health. Prior to that, he held the same position at Sorbent Therapeutics. O’Neil has also served as the vice president of finance and marketing at ChemGenex Pharmaceuticals and as a team member at HX Diagnostics. O’Neil holds a bachelor’s degree in international relations from Pomona College and master’s degree in business administration from the University of California, Los Angeles. He lives in San Francisco, California, United States.
Follow Tom O’Neil:
About Nodality, Protagonist Therapeutics: Protagonist Therapeutics develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies.
David McClung
Vice President of Finance & Accounting(Chief Financial Officer) of BioCardia
David McClung has served as our Vice President of Finance since 2016 and has been with the company since September 2013. Mr. McClung has more than 20 years of finance and accounting experience in publicly and privately financed organizations, including startup enterprises, middle-market businesses and large public companies. For the last ten years he has held leadership roles in emerging businesses, primarily life science ventures, most recently as the Controller for Sonitus Medical Inc. and NextWave Pharmaceuticals, Inc. He spent his early career in public accounting, beginning with KPMG LLP, after which he gained broad financial and operational experience directing the North American audit group for The Clorox Company and serving as Director of Internal Audit for Matson Navigation, Inc. Mr. McClung earned a Bachelor of Arts degree in Accounting from Georgia State University, graduating with honors. He is an actively licensed CPA and member of the AICPA and the California Society of CPAs.
Follow David McClung:
About BioCardia: BioCardia is a clinical-stage regenerative medicine company.
Christopher Senner
Executive Vice President and Chief Financial Officer of Exelixis
Chris Senner is Executive Vice President and Chief Financial Officer at Exelixis. Since July 2015, Mr. Senner has held this role with responsibility for ensuring the prudent management of the company’s assets, allowing Exelixis to invest in its proprietary and partnered molecules, launch new indications and otherwise advance its important work in the treatment of cancer. Prior to joining Exelixis, Mr. Senner served as Vice President, Corporate Finance at Gilead Sciences, Inc., which he joined in March 2010. At Gilead, he was accountable for controllership, tax, treasury and corporate and operational financial planning. Before joining Gilead, Mr. Senner spent 18 years at Wyeth in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth’s U.S. pharmaceuticals business and the BioPharma business unit. Mr. Senner holds a B.S. in Finance from Bentley College.
Follow Christopher Senner:
About Exelixis: Exelixis works is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases.
David Chacko
Chief Financial Officer of Erasca
David is Chief Business Officer of Erasca, bringing deep experience in strategy, finance, business development, and operations. He was previously a Principal at Versant Ventures, where he held a dual investing/operating role, helping lead investment opportunities across multiple therapeutic areas. Operationally, he was intimately involved in advancing several Versant portfolio companies through company formation, fundraising, business development, and clinical and regulatory activities. David joined Versant from Alcon, where, as Chief of Staff to the CEO, he worked alongside the executive leadership team to develop and implement high priority corporate initiatives to accelerate growth and innovation. Prior to Alcon, David was an Engagement Manager at McKinsey, leading multiple teams serving pharmaceutical and medical device clients, across sales and marketing, R&D, finance, and other functions. Previously, David worked at SR One, the venture capital arm of GSK. He also worked at Amgen in commercial operations and at Morgan Stanley in investment banking. David holds an M.D. from the University of Pennsylvania, where he was President of the medical student body and an MBA from the Wharton School. He earned an MPhil from Oxford University as a Marshall Scholar, as well as undergraduate degrees in biology and business from the University of Southern California, where he graduated as the University Valedictorian.
Follow David Chacko:
About Erasca: Erasca is a developer of oncology drugs intended to provide precision oncology options.
Lynsey Wenger
CFO & CSO of Calysta
Lynsey Wenger joined Calysta in 2016 as Chief Financial Officer and Chief Sustainability Officer. She is responsible for the company’s financial strategy, planning and management, and for expansion and implementation of Calysta’s long term sustainability strategy and programs. Ms. Wenger joined Calysta following a 16-year career with The Goldman Sachs Group, where she spent the greater part of the last decade specializing in global natural resources investment banking. She will have responsibility for the company’s financial strategy, planning and management, and for expansion and implementation of Calysta’s long term sustainability strategy and programs. During Ms. Wenger’s career at Goldman Sachs, she managed and led investment banking activities in global natural resources ranging from international mergers and acquisitions and IPOs to multimillion-dollar equity transactions and debt placements. Her industry experience includes natural gas and electric utilities, power, renewables and alternative energy. Most recently, Ms. Wenger served as a Vice President in the Investment Banking Division, with responsibility for transactions in the corporate power and utility sectors. Previously, she served in the Americas Financing Group as Head of Investment Grade Power, Utility and Midstream Debt Capital Markets. Earlier in her career she held positions in Equity Derivative Sales in the United States and Australia. Ms. Wenger holds an MBA from The Wharton School at the University of Pennsylvania and a Bachelor of Arts degree from Duke University.
Follow Lynsey Wenger:
About Calysta: Calysta Energy develops a new biological gas-to-liquids™ (BioGTL™) and biological gas-to-chemicals (BioGTC™) technology using natural gas.
Ivan Ivankovich
CFO of Sanguine
Co-Founder of Full Stack Finance.
Follow Ivan Ivankovich:
About Full Stack Finance, LLC, Markaaz, Sanguine: Sanguine develops innovative technology solutions for clinical researchers.
Bing Zhu
CFO of Crown Bioscience
Mr. Bing Zhu is responsible for overseeing our corporate finance and IT departments. From 2010 to 2013, Mr. Zhu was the chief strategy officer of LDK Solar Co., Ltd., a company listed on the New York Stock Exchange, and concurrently an executive director and the chief financial officer of LDK Silicon & Chemicals Technology Co., Ltd., a subsidiary majority owned by LDK Solar Co., Ltd. From 2008 to 2010, Mr. Zhu was the chief financial officer and a director of Chemspec International Ltd., a company listed on the New York Stock Exchange. From 2005 to 2008, Mr. Zhu was with Canadian Solar Inc., whose head office is based in Suzhou, China, as a director and the chief financial officer. Prior to that, Mr. Zhu worked for four years in commercial banking in Toronto, Canada. From 1996 to 2000, Mr. Zhu was the Shanghai chief representative of Raytheon Corporation. From 1993 to 1996, Mr. Zhu was a corporate banking account manager for Banque Indosuez. Mr. Zhu holds a master of business administration degree from China Europe International Business School and a bachelor’s degree in business management from Zhejiang University of Technology in China.
Follow Bing Zhu:
About Crown Bioscience: CrownBio is helping provide clarity of action in the fight against cancer and diabetes.
McDavid Stilwell
Chief Financial Officer of Coherus Biosciences
McDavid Stilwell is the Chief Financial Officer at Coherus BioSciences.
Follow McDavid Stilwell:
About Coherus Biosciences: Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.
William R. Anderson
Co-founder & Chief Financial Officer of GENiSYSS
Co-founder, Chief Financial Officer (CFO), and Chairman of the Board, Bill Anderson has spent 50 years in engineering, sales and marketing, and executive management. He served as Vice President of Engineering, VP of Sales & Marketing, COO, President, and CEO of Applied Magnetics Corporation (AMC), a Santa Barbara-based international manufacturer of components for the computer peripheral industry. During his 30-year tenure, the company grew from 140 to over 10,000 employees with revenue growth from less than $50 million to over $250 million per year. Anderson retired in 1994, founding a consulting company, “International Business Expansion”, that continues to serve both startup and established businesses. In early 1996, he co-founded Catalytic Solutions, Inc. (CSI), a developer and manufacturer of advanced catalyst products for vehicle and energy applications, serving as the company’s CEO and Chairman. Anderson retired from CSI at the end of 2004, as the company was beginning preparations for its IPO. With a degree in physics from UCSB, he brings knowledge and experience in all aspects of launching and growing a business, internationally.
Follow William R. Anderson:
About GENiSYSS: GENiSYSS is a DNA vault that allows its users to store physical DNA and related personal and medical information on a device.
Craig Carlson
Chief Financial Officer of Stemedica Cell Technologies
Follow Craig Carlson:
About Stemedica Cell Technologies: Stemedica Cell Technologies is a clinical-stage biopharmaceutical company focused on the development and commercialization.
Jeffrey H. Cooper
Chief Financial Officer of Humanigen
Follow Jeffrey H. Cooper:
About Humanigen, Sierra Oncology: Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.
Cameron Durrant
Chairman, CEO and Interim CFO of Humanigen
Follow Cameron Durrant:
About Humanigen: Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.
Gavin Wood
Chief Financial Officer of Abcam
Gavin is a chartered accountant who started his career in practice in London before moving to Grant Thornton’s Thames Valley office. Gavin was Executive Vice President and Chief Financial Officer in 2013. Gavin joined Affymetrix in 2006 and has held a number of financial roles, including Vice President, Finance, International Controller, responsible for Europe and Asia Pacific. Prior to joining Affymetrix, Gavin held a number of positions at the Unipart Group of Companies, including Business Unit Controller and Business Process Manager for implementing major enterprise resource planning systems in North America. Gavin has over twenty years’ experience as an accounting professional with broad, and international exposure in a number of sectors and roles including Corporate, Statutory and Operational accounting, Project Management and Investor Relations. Gavin is a Chartered Accountant who qualified with the London Accountancy Practice Morgan Brown Spofforth in 1997 before continuing his career with Grant Thornton LLP.
Follow Gavin Wood:
About Abcam: An innovator in life science reagents and tools serving life science researchers globally to achieve their mission, faster.
Knud Mueller
Sr. Vice President & Chief Financial Officer of Beckman Coulter
Follow Knud Mueller:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Jay File
Chief Financial Officer of Evofem Biosciences
Jay File has served as our Chief Financial Officer at Evofem Biosciences since 2015. He has approximately 25 years of diverse accounting and finance experience within a variety of both public and private biotechnology companies. Most recently, he provided executive financial and accounting oversight services to various biotechnology companies in San Diego, assisting in their initial public offering process and helping to establish and improve their accounting and finance operations as publicly-traded entities. Prior to this, Mr. File was Senior Director and Controller of Sequenom, Inc, a diagnostic company that developed and commercialized molecular diagnostics testing services for the women’s health market. During that time, he served as Treasurer of their diagnostic subsidiary and providing assistance in the raise of over $400 million in combined equity and convertible note offerings. He also assisted in the commercial launch of four diagnostic tests in a two-year period, which included Sequenom’s revolutionary noninvasive prenatal test for Down syndrome. Earlier in his career he worked for approximately ten years in public accounting, primarily with Arthur Andersen LLP, where he worked with a variety of clients assisting with attestation and periodic reporting requirements, public offerings and acquisitions. He graduated from Central Washington University with a Bachelor’s of Science in Accounting and International Business and is a Certified Public Accountant (inactive).
Follow Jay File:
About Evofem Biosciences, WCG Cares: Evofem is a biotechnology company that develops reproductive and contraceptive care products for women worldwide.
Dan T. Bessey
CFO of Thermogenesis
Follow Dan T. Bessey:
About Thermogenesis: Thermogenesis, a health care company, focuses in development of automated technologies for cell-based therapeutics and bioprocessing.
Andrew Ruff
CFO of Liquid Grids
Andrew Ruff brings a wealth of managerial accounting experience to LiquidGrids. With experience as a Principal of TGG Accounting, Chief Executive Officer at The Garrett Group and Controller in the U.S. Marine Corps, Mr. Ruff leads LiquidGrids non-core business functions including accounting, human resources, compliance, risk mitigation and facilities. The integration of key performance metrics and financial reporting within all of LiquidGrids operations is Mr. Ruff’s primary focus of effort. Mr. Ruff has led multiple companies through successful start-ups, capital raises, operating cycles and exits. Mr. Ruff’s academic background includes a B.S. in Economics from the United States Naval Academy, where he graduated as the Brigade Executive Officer.
Follow Andrew Ruff:
About Gastronome Ventures, Liquid Grids, TGG Accounting, TGG Accounting: Liquid Grids empowers healthcare companies to listen, understand, and strategically engage in online health dialogues.
Michael Watts
Chief Financial Officer of Sonendo
Michael brings over 20 years of experience within the medical device and healthcare industries. Prior to joining Sonendo, Michael was the Chief Financial Officer of The HydraFacial Company, a leading manufacturer and marketer of non-invasive equipment and consumables used in aesthetic skin health treatments. Michael has held senior financial leadership positions within Johnson & Johnson, Zimmer Holdings and Danaher Corporation. Early in his career, he spent five years as an auditor in public accounting and is a Certified Public Accountant (Massachusetts). Michael holds a Bachelor of Science degree in Accounting from the University of Massachusetts and Master of Science from Bentley College.
Follow Michael Watts:
About Sonendo: Sonendo is a developing innovative and disruptive technologies to transform endodontic therapy.
John Beck
Acting Chief Financial Officer of AEGEA Medical
John started BeckCFO in 2007 and brings over 30 years of experience in financial management, strategic planning and execution for technology firms. John has worked with early stage companies in life sciences (medical device and pharmaceutical), fabless semiconductor, software and software as a service, hardware systems, and services. John has held full-time CFO positions with both public and private companies, and, in addition to finance, has broad experience managing cross-functional areas such as IP management, legal, treasury, risk management, HR, IT and facilities. John’s background also includes managing the accounting, finance and reporting requirements of European and Asian offices. Before starting BeckCFO, John previously served as CFO for several companies including: Silicon Bandwidth, Inc., nDSP Corporation (acquired by PixelWorks), Sigma Designs, Inc., Augeo Software, Meta-Software, Inc. (acquired by Synopsys), Sellectek Incorporated, RayLAN Corporation, Optimem and Spectra Logic subsidiaries of Cipher Data Products, and Minton Company. Prior to his tenure at technology firms, John held senior audit positions at Ernst & Young and KPMG Peat Marwick certified public accounting firms. John earned a B.S. degree in Commerce with an Accounting emphasis, cum laude, from Santa Clara University. He is also a licensed C.P.A. (inactive), with the State of California.
Follow John Beck:
About AEGEA Medical, CloudPhysics: AEGEA Medical manufactures surgical and medical instruments.
Scott Gorton
CFO of Apton Biosystems
Follow Scott Gorton:
About Apton Biosystems, Cloudleaf, Precursor Energetics: Apton Biosystems develops a high-throughput and low-cost sequencing platform that revolutionizes the availability of genetic analysis.
Ryan Martins
Chief Financial Officer of 89bio
Ryan Martins is chief financial officer at 89bio.
Follow Ryan Martins:
About 89bio: 89Bio is a biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders.
Graham Cooper
COO, CFO of Assembly Biosciences
Graham Cooper joined us as Chief Financial Officer in February 2013. Prior to joining us, during 2012, Graham Cooper was the Executive Vice President, Finance and Chief Financial Officer of Geron Corporation, a biopharmaceutical company focused on cancer therapies. From 2006 until 2011, Graham Cooper served as Senior Vice President, Chief Financial Officer and Treasurer of Orexigen Therapeutics, Inc., a biotechnology company focused on obesity. From 1999 to 2006, Graham Cooper held positions of increasing responsibility including Director, Health Care Investment Banking, at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From August 1992 to January 1995, he worked as an accountant at Deloitte & Touche, and was previously a C.P.A. Graham Cooper holds a B.A. in Economics from the University of California at Berkeley and an M.B.A. from the Stanford Graduate School of Business.
Follow Graham Cooper:
About Assembly Biosciences, Beam Therapeutics: Assembly Biosciences, Inc. is a public biotechnology company and provider of oral biologic therapeutics.
Scott Giacobello
Chief Financial Officer of GW Pharmaceuticals
Scott Giacobello brings 25 years of finance and operational experience to GW Pharmaceuticals.He is an accomplished executive who most recently and until its acquisition by Allergan, Inc. in late 2016, served as Chief Financial Officer for Chase Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, Inc., most recently serving as Vice President of Finance for Global Research & Development. While at Allergan, he also served as Vice President of Corporate Finance and Vice President of Internal Audit & Compliance. Scott’s previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP. Mr. Giacobello holds a bachelor’s degree in business administration from the University of Notre Dame and is a Certified Public Accountant.
Follow Scott Giacobello:
About GW Pharmaceuticals: GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics.
John Borgeson
Chief Financial Officer of ALX Oncology
John Borgeson is our Chief Financial Officer and has served in this position since June 2014. Borgeson brings over 25 years of pharmaceutical industry experience in finance, strategy and operations on a global scale. Previously Borgeson was a Vice President of Finance at Pfizer and a member of Pfizer’s Global Financial Leadership Team. Borgeson’s roles at Pfizer included CFO for Pfizer’s biotherapeutics division and corporate tax executive with responsibility for US and Europe. Under Borgeson’s leadership, Pfizer completed a transformational restructuring of the global tax group that was replicated by other Fortune 50 companies. Borgeson has more recently led finance for a variety of private biotech companies, including Labrys Biologics, which was acquired by Teva Pharmaceuticals for $825 million. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant. He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
Follow John Borgeson:
About ALX Oncology, Kodiak Sciences: ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Kelly Deck
Chief Financial Officer of Inhibrx
Kelly Devine Deck is the Chief Financial Officer at InhibRx.
Follow Kelly Deck:
About Inhibrx: Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.
Anthony M. Rimac
Chief Financial Officer of Cognoa
Follow Anthony M. Rimac:
About Cognoa: Cognoa is a behavioral health company focused on improving the lives and outcomes of children and families living with behavioral conditions
Mike Johnson
CFO of Cord Blood Registry
Mike Johnson joined CBR as CFO in January 2013. Mike was most recently the CFO of Fenwal, a global blood technology company dedicated to supporting transfusion medicine and cell therapies. He successfully managed a carve-out of the Fenwal business from Baxter in 2006. From 2006 to 2012 he led the global finance and IT organizations through a business transformation that supported international integration of a stand-alone business and resulted in significant value creation. TPG, a large private equity firm, recently sold the business to Fresenius. Prior to Fenwal, he spent almost 10 years in senior financial roles at Dade Behring, a leading medical diagnostics company, including Corporate Controller, and V.P. Finance for the manufacturing, supply chain and R&D organizations. Mike has a B.S. in Accounting from the University of Illinois and an M.B.A. from the University of Chicago.
Follow Mike Johnson:
About Cord Blood Registry: Cord Blood Registry is the world’s largest newborn stem cell company.
Jeff Mack
CFO of Potrero Medical
Follow Jeff Mack:
About Potrero Medical: Potrero Medical is a predictive health company that is developing the next generation of smart sensors and artificial intelligence.
Anurag Goel
CFO, Board Of Directors & Investor of Celltheon
Anurag Goel is the CFO/Business Development/Board Of Directors at Celltheon.
Follow Anurag Goel:
About Afferent Technologies, Celltheon: Celltheon is a cell line development and expression technologies company.
William G. Harris
Senior Vice President of Finance & Chief Financial Officer of Xenoport
William G. Harris is the chief financial officer of [Xenoport](https://www.crunchbase.com/organization/xenoport), a biopharmaceutical company that develops a portfolio of product candidates to treat neurological disorders. He was previously the CFO of Coulter Pharmaceutical. Prior to that, he held several positions at Gilead Sciences. Harris holds a bachelor’s degree from the University of California and an MBA from Santa Clara University.
Follow William G. Harris:
About Xenoport: XenoPort is a biopharmaceutical company that develops a portfolio of product candidates to treat neurological disorders.
Brandon Poe
Chief Financial Officer of Jumpcode Genomics
Brandon Poe is the Chief Financial Officer at Jumpcode Genomics.
Follow Brandon Poe:
About Jumpcode Genomics: JUMPCODE’s CRISPR-mediated rRNA depletion kits remove nucleic acids from sequencing workflows to improve sensitivity and performance.
Steve Krognes
CFO of Denali Therapeutics
Mr. Steve Krognes serves as Senior Vice President, Regional Head of Finance and IT and Chief Financial Officer of Pharma North America at Genentech, Inc. Mr. Krognes joined Roche in January 2004 as global head of Mergers and Acquisitions. He served as Head of Corporate Finance-Corporate Development of Roche Holding AG. In this role, he led Roche’s internal Mergers and Acquisitions group and was responsible for all Roche transactions worldwide. Prior to joining Roche Holding AG, Mr. Krognes worked as a venture capitalist in Scandinavia, as a mergers and acquisitions investment banker with Goldman Sachs and Danske Bank, and as a management consultant with McKinsey & Co. He has been a Director of California Healthcare Institute since August 2010. He is a second lieutenant in the Royal Norwegian Air Force. Mr. Krognes holds a Master’s in Business Administration from the Harvard Business School and a Bachelor’s in Economics from the Wharton School at the University of Pennsylvania.
Follow Steve Krognes:
About California Healthcare Institute, Denali Therapeutics: Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Olivia K. Bloom
CFO, Treasurer & EVP of Geron
Olivia K. Bloom is the chief financial officer, treasurer, and executive vice president of [Geron](https://www.crunchbase.com/organization/geron-corp#/entity), a biopharmaceutical company that discovers and develops therapeutic products for cancer. Before joining Geron, she started her career in public accounting at KPMG Peat Marwick and became a certified public accountant in 1994. Bloom holds a bachelor’s degree in business administration from the University of California, Berkeley.
Follow Olivia K. Bloom:
About Geron: Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel,
Kamal Adawi
Chief Financial Officer of Exagen
Follow Kamal Adawi:
About Exagen: Exagen is a patient focused, discovery-driven life science company serving patients affected by autoimmune rheumatic diseases.
Mark Kaufmann
Chief Financial Officer & Chief Business Officer of ESCAPE Bio
Mr. Kaufmann has been a biotech executive with leadership experience as a CEO, CBO, COO and CFO at prior companies. Most recently he was the Chief Financial Officer and Head of Corporate Development at Ardelyx, Inc (ARDX), where he led the IPO and subsequently raised over $500 million in equity financings and completed $1.0 billion of licensing deals during his tenure. Previously he spent over a decade forming and leading multiple biotech companies in Montreal. He started his career at MedImmune, Inc.
Follow Mark Kaufmann:
About ESCAPE Bio: ESCAPE Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases.
Sarita Evans
Co-Founder and CFO of Spectrum CannaLabs
Sarita Evans is the co-founder and CFO of Spectrum CannaLabs.
Follow Sarita Evans:
About Spectrum CannaLabs: Spectrum CannaLabs is an analytical testing laboratory that provides testing solutions for legal cannabis products.
Michael Leonard
Chief Financial Officer & Chief Operating Officer of Trigemina
Follow Michael Leonard:
About AtomBeam Technologies, Motif, Trigemina: Trigemina develops non-opiate drug formulations and delivery systems for pain therapy.
Trisha Millican
CFO of Metacrine
Follow Trisha Millican:
About Metacrine: Metacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs.
Kevin D. Green
VP, Finance & CFO of Cerus
Follow Kevin D. Green:
About Cerus: Cerus is a biomedical products company focused in the field of blood safety.
Eric d’Esparbes
Senior Vice President & Chief Financial Officer of Innoviva
Eric d’Esparbes is SVP and CFO at Innoviva. From 2010 to 2014, Mr. d’Esparbes served as the Chief Financial Officer of Joule Unlimited, a biotechnology company. Prior to Joule Unlimited, he was the Vice President, Finance, of AEI, a global emerging markets energy company. Eric arned a BAA in International Finance from the University of Montreal’s Hautes Etudes Commerciales in Montreal, Canada.
Follow Eric d’Esparbes:
About Innoviva: Innoviva is committed to building long-lasting value and improving patient care.
Xavier Aguilera
Executive Vice President/Chief Financial Officer of Imaging3
Mr. Aguilera has over 30 years experience in finance, marketing, international finance and administration. Having served as both a domestic and international banker, his experience in administration has enabled him to help companies achieve high levels of success. For approximately10 years prior to his employment by the Company, Mr. Aguilera served as a consultant in the medical management field. He holds a Bachelors degree in Business from California State University at Northridge and a Certificate of Medical Management from the University of California at Los Angeles.
Follow Xavier Aguilera:
About Imaging3: Imaging3 is a global manufacturer of medical devices, equipment, and imaging tools for the healthcare industry.
Mike Anthofer
CFO Consultant of Murdock Martell, Inc
Mike Anthofer is the CFO Consultant of Murdock Martell.
Follow Mike Anthofer:
About Mojo Networks, Murdock Martell, Inc: Specialized finance, accounting and HR solutions on demand
Michael Farrow
CFO of PipelineRx
Mr. Farrow is a seasoned Financial leader with over 20 years of experience driving improved financial performance across a wide range of industries. Prior to joining PipelineRx, Mike served as a CFO for CloudMade, a leader in location based technologies working with the world’s leading automotive and consumer electronics OEMs. Previously, he served as CFO for leading digital media companies NetShelter Technology Media and Jumpstart Automotive Media which deliver internet advertising across technology and automotive-related websites, respectively. He was also the top Financial Manager for fastest growing division at EarthLink, a Fortune 1000 company. Mr. Farrow earned a B.S. in Finance from the University of Arizona and has his M.B.A. from the USC Marshall School of Business.
Follow Michael Farrow:
About PipelineRx: PipelineRx is a clinical telepharmacy services company that offers clinical telepharmacist teams to its hospital clients.
David Horin
Interim Chief Financial Officer of Mustang Bio
Follow David Horin:
About Chord Advisors, Mustang Bio: Mustang Bio is a clinical-stage biopharmaceutical company .
Michael Byrnes
Chief Financial Officer of Effector Therapeutics
Michael Byrnes joined eFFECTOR Therapeutics as Chief Financial Officer in 2020.
Follow Michael Byrnes:
About Effector Therapeutics: Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.
Paul J. Lytle
Chief Financial Officer of Avid Biosciences
Paul J. Lytle has served as Chief Financial Officer since August 2002 and has over 17 years of finance and accounting experience. Mr. Lytle oversees various functions, including finance and accounting, financial reporting, Corporate Governance, investor relations, human resources and information technology. Mr. Lytle started with Peregrine in March 1997 as Corporate Controller and has held positions of increasing responsibility at the Company. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as the Company’s Corporate Secretary in 2000. Prior to joining Peregrine, Mr. Lytle worked for Deloitte & Touche LLP. Mr. Lytle holds a B.S. in Business Administration from the California State University at Long Beach and is a certified public accountant in the State of California and a member of the American Institute of Certified Public Accountants.
Follow Paul J. Lytle:
About Avid Biosciences: Avid Bioservices’ expansion will double existing capacity to service both a $40m backlog and its owner Peregrine.
Paul A. Stone
Chief Financial Officer & General Counsel of IDEAYA Biosciences
Stone Paul A. joined IDEAYA Biosciences as Chief Financial Officer, General Counsel in 2018.Paul A. Stone, J.D. joined 5AM Ventures in July 2009 as General Counsel and Chief Operating Officer. In addition to his legal and operational responsibilities, he serves as a Board Observer at Kinestral, Rennovia and Wildcat. Mr. Stone has held managerial and operating roles at several private and public biopharmaceutical companies. Most recently he was General Counsel and Senior VP Intellectual Property at Ethos Pharmaceuticals. Previously he was Senior VP, General Counsel, and Chief Patent Counsel at Ilypsa (acquired by Amgen). Prior to Ilypsa, he was VP, Chief Patent Counsel for Symyx (IPO in 1999). Mr. Stone received his J.D. from the University of Wisconsin Law School in 1995 and practiced as a Patent Attorney at Senniger, Powers, Leavitt & Roedel. He taught patent law, trade secrets law and licensing as an adjunct professor at the University of Missouri and Santa Clara University.
Follow Paul A. Stone:
About 5AM Ventures, IDEAYA Biosciences: IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality
Avi Lifshitz
CFO of Pimi Agro
Mr. Avi Lifshitz is our Chief Financial Officer, and brings to Pimi more than 25 years of experience in accounting, finance and business management. , Mr. Lifshitz is serving for 16 years as CFO of Jordan Valley Semiconductors Ltd which is preparing its financial statement in accordance with the US GAAP. He is the Secretary of Jordan Valley Semiconductors UK Ltd and Jordan Valley Semi Conductors Gmbh (Germany). He has joined Meiri-Lifshitz Accounting firm in 1990 and is a partner since then. Mr. Lifshitz is a director in Bede Scientific Inc (US) in Efrat Consultants Ltd (ISR) and in Ed-Wise Ltd (ISR). Mr. Lifshitz teaches at the Technion-Israel Institute of Technology where he won an award for excellence in 1998. He is certified as a public accountant in Israel, and holds a B.A. in economics and accounting from Haifa University.
Follow Avi Lifshitz:
About Pimi Agro: Pimi Agro was established in 2004 to capitalize on many years of research in developing eco-friendly solutions.
Jim Jungwirth
Co-Founder, Vice President, CFO of Harbor MedTech
Follow Jim Jungwirth:
About Harbor MedTech: Harbor MedTech develops and commercializes tissue regeneration products for chronic wounds, hernia and joint repair, and more.
Laurie Stelzer
Chief Financial Officer of Halozyme Therapeutics
Laurie Stelzer has served as our Executive Vice President and Chief Financial Officer since March 2020. Laurie has over 20 years of experience in biopharmaceutical management, including leading teams in finance, treasury, investor relations, business development and emerging markets. Most recently, Laurie served as Chief Financial Officer of Halozyme Therapeutics, Inc. Prior to joining Halozyme, Laurie served as SVP of Finance for R&D, Technical Operations and Business Development, and was previously Division CFO for Regenerative Medicine, at Shire Plc. Before Shire, she spent 15 years at Amgen Inc. in senior leadership roles in finance and business development with responsibilities including the U.S., Canada and International Markets, ultimately serving as the company’s acting treasurer, and playing an integral role in the original build of their immunology business. Laurie earned her B.S. in Accounting from Arizona State University and an M.B.A. from University of California, Los Angeles, Anderson School of Management. She currently serves on the board of directors for Surface Oncology, Inc.
Follow Laurie Stelzer:
About Arena Pharmaceuticals, Halozyme Therapeutics: Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets.
Lynne Rollins
CFO of Gene Sciences, Inc.
Lynne has over 25 years of experience in accounting and finance, and has worked with numerous startup companies. At Gene Sciences, she is responsible for finance and all contract negotiations.
Follow Lynne Rollins:
About Gene Sciences, Inc.: Gene Sciences Inc. is developing novel DNA targeted therapeutics for the treatment of human genetic diseases.
Zack McNealy
CFO of Inception Sciences
Zack McNealy joined Ventus Therapeutics as CFO in 2019.Zack McNealy is the Vice President, Finance responsible for Versant’s domestic and international management company entities. Zack also works extensively with a number of Versant’s biotech portfolio companies on their international structuring and operational setup. Zack joined Versant after spending seven years at Biotie Therapies (formerly Synosia Therapeutics) where he was Vice President, Finance supporting the U.S. and Swiss operations of the company. Prior to Biotie, Zack spent ten years at Johnson & Johnson as Plant Controller, Finance Manager and Financial Analyst. Zack received an MBA from the Wharton School, University of Pennsylvania and a BS in finance and accounting from Miami University (Ohio).
Follow Zack McNealy:
About Inception Sciences, Ventus Therapeutics: Inception Sciences creates therapies with transformative potential to address diseases and disorders with significant unmet need.
Jeet Mahal
Chief Financial and Business Officer of Jasper Therapeutics
Jeet Mahal is the Chief Financial and Business Officer at Jasper Therapeutics.
Follow Jeet Mahal:
About Jasper Therapeutics: Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning and therapeutic.
Andrew A. Sauter
Chief Financial Officer of Lifemax
Follow Andrew A. Sauter:
About Lifemax, LifeSci Venture Partners: Lifemax is a biotechnology company that develops therapeutics for various medical sectors.
Erin Lafferty
CFO of Accumen
Follow Erin Lafferty:
About Accumen: Accumen partners with hospitals and health systems to deliver Laboratory Excellence and Comprehensive Patient Blood Management.
Prathyusha Duraibabu
CFO of Sangamo Therapeutics
Prathyusha Duraibabu is the CFO at Sangamo Therapeutics.
Follow Prathyusha Duraibabu:
About Sangamo Therapeutics: Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.
Tom Gruber
COO and CFO of CDx Life
Tom has over 20 years of experience in financial and senior executive management from well known, publicly traded technology companies. He has worked as the CFO for Western Digital and as the CFO and COO for I/O Magic. Tom holds an MBA from Pepperdine University.
Follow Tom Gruber:
About CDx Life: MyDx (My Diagnostic) is the world’s first portable analyzer for everyone – a simple and affordable device.
Mitch Levine
Chief Financial Officer of OncoCyte
Mitch Levine is the Chief Financial Officer at OncoCyte.
Follow Mitch Levine:
About OncoCyte: OncoCyte is a biotech company helping save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer.
Gordon Galloway
CFO of Vali Nanomedical
Gordon Galloway received his MBA from the UCLA Anderson School of Management and his BSBA from the UC Berkeley Haas School of Business. Of nine years working in finance, he spent three in banking and two at Stryker Corporation, a Fortune 500 manufacturer and technology leader in the medical device industry. At Stryker, he helped support the acquisition of two entrepreneurial startups in order to commercialize cutting-edge health care technology around the world. He has worked alongside Dr. Gray on a variety of projects for over a decade, and became Vali’s CFO in 2014.
Follow Gordon Galloway:
About Vali Nanomedical: Vali is a biotechnology company founded in 2013.